Vaccine Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Colorectal Cancer

Colorectal cancer outcomes were comparable between two chemotherapy regimens

According to recent research published in the journal Annals of Oncology, "A phase III study was started to compare oxaliplatin/5FU/LV in the first-line with bolus FU/LV in metastatic colorectal cancer. Three hundred and two patients were randomised and received bolus 5-FU 425 mg/m² day 1-5, FA 20 mg/m² day 1-5, q 4 wk or oxaliplatin 85 mg/m², 2 h-infusion, FA 200 mg/m², 1-h infusion. 5-FU 2600 mg/m², 24-h infusion day 1, q 2 wk."

"The primary endpoint was response rate (RR)," explained G.A.P. Hospers and...

• View Other Issues of Vaccine Weekly
  
• View Other NewsRx Publications